Atopic Dermatitis

Investigators believe these results could help improve disease recognition and diagnosis while supporting development of personalized prevention and therapy.

Experts in dermatology comment on the heterogeneity of atopic dermatitis and how this affects clinical practice decisions, patient quality of life, and disease burden.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, provide insight into pediatric atopic dermatitis, focusing their discussion on the pathophysiology, prevalence, and disease symptomology.

New sensitizations to 2 or more allergens between baseline and 12 months were significantly lower in the sublingual group, compared to the control group.

Proton beam therapy has been heavily adopted for treating patients with nasopharyngeal cancer, and a high incidence of severe ARD has been reported in this patient population.

Though the association between pediatric and parental AD has been detailed in previous literature, differing odds ratios for AD have been recorded throughout the years.

There are 8 biologic therapies currently approved for GPP in Japan, with IL-inhibitors being the predominant therapeutic option.

Between 1980 and 2019 in Spain, a total of 2914 deaths were attributable to SSc, with rates increasing in a 4-year period in the 1980s.

Changes in disease severity were not observed in patients treated with acupuncture or osteopathic medicine, though a reduction in topical corticosteroid use was recorded.

Reductions in pethidine and diclofenac use was also observed in patients treated with the topical ointment.

The recommendations are for how stakeholders and policy makers should support improvements in managing atopic dermatitis to achieve better disease control and ultimately reducing the costs and burden on individuals, society, and the economy.

New phase 3 data indicates significant improvements in disease severity in children 1-11 years old with eosinophilic esophagitis.

Previous literature indicated a higher prevalence of eczema in children who live in areas with hard water, but this association was not explored in adults until now.

The topical therapy has been under investigation as a first-in-class therapy for this highly contagious skin condition.

Dr. Karan Lal provides an overview of laser therapy for acne, and speaks on the "phenomenal" responses observed in patients with the first and only FDA approved laser treatment, AviClear.

New 21-month data from the SUSTAIN trial found that patients with no history of biologic therapies responded well to secukinumab.

Investigators suggest parents and clinicians should be mindful of children with suspected ACD with a history of exposure to jewelry, clothing, and belts with cobalt.

Investigators say the increased risk of emergency room admissions and urgent healthcare use among patients with concomitant AD and asthma warrants a better understanding of disease interplay.

Previous research had resulted in conflicting results regarding the drug survival of guselkumab, which was shown to be highest among several biologics featured in this larger study.

Nearly 40% of patients with prurigo nodularis reached clearance or almost-clearance of skin lesions following treatment with nemolizumab.

Elizabeth A. Swanson, MD, and Raj. J. Chovatiya, MD, PhD, examine challenges in managing atopic dermatitis and explore the evolving treatment landscape.

Korey Capozza, MPH; Elizabeth A. Swanson, MD; and Taylor Capps share pearls for patients and their families managing atopic dermatitis.

Korey Capozza, MPH, highlights the importance of patient advocacy in the atopic dermatitis journey.

Despite the frequency in which the ARAs were detected, investigators noted that they were not associated with any noticeable patient outcomes.

The Acne-Q and the CompAQ instruments received an “A” recommendation by investigators, though evidence on content validity and other measurement properties were lacking.

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

Raj J. Chovatiya, MD, PhD; Elizabeth A. Swanson, MD; Tina Capps; and Taylor Capps assess barriers in finding and obtaining atopic dermatitis treatments.

Elizabeth A. Swanson, MD, discusses the safety and efficacy of dupilumab in treating moderate to severe atopic dermatitis, and Taylor Capps shares her journey with dupilumab from insurance approvals through receiving treatment.

Results from a cross-sectional survey suggest consistent patient preferences for treatment outcomes and means of administration.

Dr. Cohen details the latest study from Yale, which indicated that women from lichen sclerosus had increased risk of developing depression and anxiety.